Research by a collaborative group of scientists from UC San Diego School
of Medicine, UC San Francisco and Wake Forest School of Medicine has
led to identification of an existing drug that is effective against Entamoeba histolytica. Using a high-throughput screen for drugs developed by the research team,
they discovered that auranofin (see structure) a drug approved by the US Food and
Drug Administration 25 years ago for rheumatoid arthritis -- is very
effective in targeting an enzyme that protects amebae from oxygen attack
(thus enhancing sensitivity of the amebae to reactive oxygen-mediated
killing).
Entamoeba histolytica is a protozoan intestinal parasite
that causes human amebiasis, the world's fourth leading cause of death
from protozoan parasites. It is listed by the National Institutes of
Health as a category B priority biodefense pathogen. Current treatment
relies on metronidazole, which has adverse effects, and potential
resistance to the drug is an increasing concern.
"Because auranofin has already been approved by the FDA for use in humans, we can save years of expensive development," said Reed. "In our studies in animal models, auranofin was ten times more potent against this parasite than metronidazole."
In a mouse model of amebic colitis and a hamster model of amebic
liver abscess, the drug markedly decreased the number of parasites,
damage from inflammation, and size of liver abscesses.
"This new use of an old drug represents a promising therapy for a
major health threat, and highlights how research funded by the National
Institutes of Health can benefit people around the world," said Reed.
The drug has been granted "orphan-drug" status (which identifies a
significant, newly developed or recognized treatment for a disease which
affects fewer than 200,000 persons in the United States) and UC San
Diego hopes to conduct clinical trials in the near future...
Ref : http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.2758.html
No comments:
Post a Comment